RARE CANCERPleural TumorWHO 5th Edition Classification

Malignant Mesothelioma

Rare Malignancy (< 6 cases per 100,000 / year) • Clinical Staging, Genomic Targets & Vetted Specialists

A cancer of the mesothelial lining of the chest (pleura), abdomen (peritoneum) or, rarely, the heart or testis. It is overwhelmingly caused by asbestos exposure, typically 20-50 years earlier, which makes occupational history central to diagnosis and to any compensation claim.

Request Rare Cancer Tumor Board Find NCI Treatment CentersAsk Vani AI Navigator

Emergent Referral AdvisoryImmediate Action

Certain rare malignancies progress rapidly or carry acute risk of airway obstruction, acute spinal compression, hydrocephalus, or biopsy-seeding. Do not perform needle biopsy or surgery outside of an NCI-designated specialty sarcoma or neuro-oncology unit without multidisciplinary tumor board review.

Report immediately to an emergency department or tertiary oncologist upon:

  • Take an occupational history in every unexplained pleural effusion
  • Germline BAP1 testing where there is a suggestive family history
Who It Affects

Adults over 60 with prior asbestos exposure; strong male predominance reflecting occupational patterns

Annual Incidence

Approximately 1-2 per 100,000 per year in industrialised countries; still rising where asbestos use ended late

Clinical Evidence Review

Last audited: 2026-08-13 against NCCN, ESMO, and WHO 5th ed. guidelines.

Clinical Presentation & Hallmark Symptoms

Presenting signs most frequently observed across clinical case series

Breathlessness from fluid around the lung
Chest wall pain that is persistent and often described as dull and boring
Persistent dry cough
Unintended weight loss, sweats and fatigue
Abdominal swelling and pain in peritoneal disease

Genomic Profiling & Defining Molecular Lesions

Critical diagnostic fusions, somatic mutations, and therapeutic targets

Rare malignancies frequently depend on distinct oncogenic drivers rather than conventional environmental carcinogens. Comprehensive Next-Generation Sequencing (NGS comprehensive panel) and FISH/IHC are mandatory to establish the true diagnosis and screen for basket trial agents.

BAP1 loss including germline (BAP1 tumour predisposition syndrome)CDKN2A homozygous deletionNF2Calretinin and WT1 positivity by IHC

Standard-of-Care Treatment Protocol

Frontline and multimodal strategies established under international consensus guidelines

1

Nivolumab plus ipilimumab as first-line therapy, particularly for non-epithelioid histology

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

2

Pemetrexed-platinum chemotherapy, with or without bevacizumab

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

3

Pleurectomy/decortication in selected fit patients as part of multimodal therapy

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

4

Cytoreductive surgery with HIPEC for peritoneal mesothelioma, which has a far better outlook

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

5

Pleurodesis or indwelling pleural catheter for effusion control

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

6

Early specialist palliative care and support with occupational compensation claims

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

Clinical Trial Advisory: For rare and ultra-rare malignancies, enrollment in an active clinical trial or expanded-access program is widely considered the preferred standard of care by ASCO and NCCN panels.

Prognosis & Disease Trajectory

Objective clinical outlook without false reassurance

Poor for pleural disease, with median survival historically around 12-18 months, extended by immunotherapy in the non-epithelioid group. Epithelioid histology does better than sarcomatoid. Peritoneal mesothelioma treated with complete cytoreduction and HIPEC is a genuine outlier, with median survival measured in years.

Note: Statistics reflect cohort averages. Individual outcomes depend heavily on performance status, resectability, biomarker expression, and timely access to specialized tertiary care.

Active Research, Biomarkers & Clinical Trials

Novel investigational agents, phase I/II trials, and international rare disease consortia

Immunotherapy combinations and maintenance strategies, BAP1-directed synthetic lethality including EZH2 and PARP inhibition, and CAR-T against mesothelin are the principal research directions.

Need Help Matching to an Active Rare Cancer Trial?

ByOnco scans ClinicalTrials.gov, NCI trial networks, and institutional registries for open patient cohorts.

Request Trial Match
Expert Clinicians

Verified Specialists for Malignant Mesothelioma

Browse All Oncologists

Dr. Hedy Lee Kindler

Medical Oncologist

25+ yrs exp

University of Chicago

Chicago, USA

Medical OncologyMesotheliomaPemetrexed Trials
Vetted DirectoryConsult Specialist

Dr. Vyas Prasad

Thoracic Surgeon

20+ yrs exp

NCID/NCCS

Singapore, Singapore

Thoracic SurgeryMesotheliomaExtrapleural Pneumonectomy
Vetted DirectoryConsult Specialist

Prof. Marc de Perrot

Thoracic Surgeon

20+ yrs exp

Toronto General Hospital

Toronto, Canada

Thoracic SurgeryMesothelioma SurgeryImmunotherapy
Vetted DirectoryConsult Specialist

Dr. S. Vijayakumar

Medical Oncologist

15+ yrs exp

Apollo Specialty

Chennai, India

Medical OncologyMesotheliomaMulti-modality Treatment
Vetted DirectoryConsult Specialist
Hospital Network

Designated Cancer Centers with Dedicated Programs

Search All 72 NCI Centers

Memorial Sloan Kettering Cancer Center

NY

NCI-Designated Comprehensive Cancer Center

World-leading rare tumor board & pediatric solid tumor protocols

Proton TherapyCAR-T Cell TherapyRobotic Surgery
1,000+ Active Clinical TrialsView Center Profile

University of Texas MD Anderson Cancer Center

TX

NCI-Designated Comprehensive Cancer Center

Largest specialized rare cancer and sarcoma multidisciplinary program

Proton TherapyCAR-T Cell TherapyCyberKnife SBRT
1,200+ Active Clinical TrialsView Center Profile

Dana-Farber / Harvard Cancer Center

MA

NCI-Designated Comprehensive Cancer Center

Pioneering genomic molecular tumor boards & rare histologies

Proton TherapyCAR-T Cell TherapyPhase I Unit
1,100+ Active Clinical TrialsView Center Profile

Mayo Clinic Comprehensive Cancer Center

MN

NCI-Designated Comprehensive Cancer Center

High-volume surgical oncology & rare endocrine/neuroendocrine expertise

Proton TherapyCAR-T Cell TherapyCyberKnife SBRT
600+ Active Clinical TrialsView Center Profile

Frequently Asked Clinical Questions

Authoritative guidance on diagnosis, tumor boards, genomic markers, and care options

Related Rare Malignancies in Catalog

rare

Cancer of Unknown Primary (CUP)

rare

Retinoblastoma

rare

Ewing Sarcoma

rare

Osteosarcoma

Independent Tumor Board Review

Facing a Diagnosis of Malignant Mesothelioma?

Rare cancers demand rare expertise. Connect your medical records to US NCI-fellowship trained oncologists, subspecialist pathologists, and active clinical trial investigators within 12 to 72 hours.

Upload Scans for Second Opinion Schedule Virtual Teleconsult